Cell子刊：厦门大学夏宁邵/罗文新团队开发基于纳米抗体的双抗ADC药物，用于胰腺癌等实体瘤治疗

Core Viewpoint - The article discusses the development of a novel bispecific antibody-drug conjugate (B6ADC) targeting TROP2 and c-Met for the treatment of pancreatic cancer, highlighting its potential to overcome limitations of existing therapies and improve treatment outcomes [3][6][9]. Group 1: Research Findings - The study successfully developed B6ADC, a nanobody-based bispecific ADC that targets both TROP2 and c-Met, demonstrating excellent antitumor activity in pancreatic cancer and various solid tumor models [4][9]. - B6ADC exhibited strong cytotoxicity against multiple cancer cell lines expressing TROP2/c-Met in vitro and showed superior tumor suppression in vivo compared to single-target ADCs and their combinations, including approved drugs like Sacituzumab Govitecan and Teliso-V [6][9]. - Notably, B6ADC can eliminate large tumors with a single low dose of 2.2 mg/kg body weight [7][10]. Group 2: Implications for Treatment - The research presents B6ADC as a promising strategy for treating pancreatic cancer and other malignancies that express TROP2 and c-Met, enhancing selectivity for tumors with dual or weak antigen expression [9][10]. - The findings suggest that TROP2/c-Met is an ideal combination target in solid tumors, with B6ADC demonstrating broad antitumor efficacy and good safety profiles [10].